Bharat Biotech completes clinical development for phase-III trials and booster doses for BBV154 intra-nasal COVID vaccine Read more
Covaxin demonstrates persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants Read more
Ocugen announces positive results for COVID-19 vaccine trial for children aged two-18 years Read more
ICMR study finds Covaxin booster dose improves effectiveness against Delta, Omicron variants Read more
CEPI partners with consortium of Bharat Biotech, University of Sydney and ExcellGene to develop ‘variant-proof’ COVID-19 vaccine Read more
Bharat Biotech must address WHO’s Covaxin supply suspension to avoid EUL cancellation, says MEA Read more